{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T21:17:47Z","timestamp":1776374267903,"version":"3.51.2"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2017,9,22]]},"abstract":"<jats:sec xml:lang=\"en\">\n            <jats:title>Background<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              Apparent treatment resistant hypertension (\n              <jats:styled-content style=\"fixed-case\">aTRH<\/jats:styled-content>\n              ) is highly prevalent in patients with type 2 diabetes mellitus (T2D) and entails worse cardiovascular prognosis. The impact of\n              <jats:styled-content style=\"fixed-case\">aTRH<\/jats:styled-content>\n              and long\u2010term achievement of recommended blood pressure (\n              <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>\n              ) values on renal outcome remains largely unknown. We assessed the role of\n              <jats:styled-content style=\"fixed-case\">aTRH<\/jats:styled-content>\n              and\n              <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>\n              on the development of chronic kidney disease in patients with T2D and hypertension in real\u2010life clinical practice.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Methods and Results<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              Clinical records from a total of 29\u00a0923 patients with T2D and hypertension, with normal baseline estimated glomerular filtration rate and regular visits during a 4\u2010year follow\u2010up, were retrieved and analyzed. The association between time\u2010updated\n              <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>\n              control (ie, 75% of visits with\n              <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>\n              &lt;140\/90\u00a0mm\u00a0Hg) and the occurrence of estimated glomerular filtration rate &lt;60 and\/or a reduction \u226530% from baseline was assessed. At baseline, 17% of patients had\n              <jats:styled-content style=\"fixed-case\">aTRH<\/jats:styled-content>\n              . Over the 4\u2010year follow\u2010up, 19% developed low estimated glomerular filtration rate and 12% an estimated glomerular filtration rate reduction \u226530% from baseline. Patients with\n              <jats:styled-content style=\"fixed-case\">aTRH<\/jats:styled-content>\n              showed an increased risk of developing both renal outcomes (adjusted odds ratio, 1.31 and 1.43;\n              <jats:italic>P<\/jats:italic>\n              &lt;0.001 respectively), as compared with those with non\u2010\n              <jats:styled-content style=\"fixed-case\">aTRH<\/jats:styled-content>\n              . No association was found between\n              <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>\n              control and renal outcomes in non\u2010\n              <jats:styled-content style=\"fixed-case\">aTRH<\/jats:styled-content>\n              , whereas in\n              <jats:styled-content style=\"fixed-case\">aTRH<\/jats:styled-content>\n              ,\n              <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>\n              control was associated with a 30% (\n              <jats:italic>P<\/jats:italic>\n              =0.036) greater risk of developing the renal end points.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              <jats:styled-content style=\"fixed-case\">ATRH<\/jats:styled-content>\n              entails a worse renal prognosis in T2D with hypertension.\n              <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>\n              control is not associated with a more\u2010favorable renal outcome in\n              <jats:styled-content style=\"fixed-case\">aTRH<\/jats:styled-content>\n              . The relationship between time\u2010updated\n              <jats:styled-content style=\"fixed-case\">BP<\/jats:styled-content>\n              and renal function seems to be J\u2010shaped, with optimal systolic BP values between 120 and 140\u00a0mm\u00a0Hg.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/jaha.117.006745","type":"journal-article","created":{"date-parts":[[2017,9,23]],"date-time":"2017-09-23T00:12:00Z","timestamp":1506125520000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":28,"title":["Resistant Hypertension, Time\u2010Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus"],"prefix":"10.1161","volume":"6","author":[{"given":"Francesca","family":"Viazzi","sequence":"first","affiliation":[{"name":"Universit\u00e0 degli Studi and IRCCS Azienda Ospedaliera Universitaria San Martino\u2010IST, Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Piscitelli","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Scientific Institute \u201cCasa Sollievo della Sofferenza\u201d, San Giovanni Rotondo (FG), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Ceriello","sequence":"additional","affiliation":[{"name":"Institut d'Investigacions Biom\u00e8diques August Pii Sunyer (IDIBAPS) and Centro de Investigaci\u00f3n Biom\u00e9dicaen Red de Diabetes y Enfermedades Metab\u00f3licas Asociadas (CIBERDEM), Barcelona, Spain"},{"name":"Department of Cardiovascular and Metabolic Diseases, IRCCS Gruppo Multimedica, Sesto San Giovanni Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Fioretto","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Padua, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Giorda","sequence":"additional","affiliation":[{"name":"Diabetes and Metabolism Unit, ASL Turin 5, Chieri (TO), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Guida","sequence":"additional","affiliation":[{"name":"Associazione Medici Diabetologi, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Russo","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"De Cosmo","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Scientific Institute \u201cCasa Sollievo della Sofferenza\u201d, San Giovanni Rotondo (FG), Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Pontremoli","sequence":"additional","affiliation":[{"name":"Universit\u00e0 degli Studi and IRCCS Azienda Ospedaliera Universitaria San Martino\u2010IST, Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"AMD\u2010Annals Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.08.036"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.189141"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06180616"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.12.061"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-016-0641-x"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00418-3"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.130764"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7176.2012.00690.x"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.07.038"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2014.03.003"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.068064"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.142"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000051"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12773"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12904"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2010.03055.x"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gft506"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03140315"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.284427"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000065"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.03850"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.08.018"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfv269"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000000350"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30754-7"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j791"},{"key":"e_1_3_4_29_2","first-page":"255","article-title":"Multicentre randomized controlled trial of angiotensin\u2010converting enzyme inhibitor\/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP\u2010ACEi trial","volume":"31","author":"Bhandari S","year":"2016","unstructured":"Bhandari S, Ives N, Brettell EA, Valente M, Cockwell P, Topham PS, Cleland JG, Khwaja A, El Nahas M. Multicentre randomized controlled trial of angiotensin\u2010converting enzyme inhibitor\/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP\u2010ACEi trial. Nephrol Dial Transplant. 2016;31:255\u2013261.","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0951"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.117.006745","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:48:09Z","timestamp":1715597289000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.117.006745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,22]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9,22]]}},"alternative-id":["10.1161\/JAHA.117.006745"],"URL":"https:\/\/doi.org\/10.1161\/jaha.117.006745","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,22]]},"assertion":[{"value":"2017-06-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-07-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-09-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e006745"}}